WO2023031855 - SUBSTITUTION OF NUCLEOTIDE BASES IN SELF-AMPLIFYING MESSENGER RIBONUCLEIC ACIDS
National phase entry:
Publication Number
WO/2023/031855
Publication Date
09.03.2023
International Application No.
PCT/IB2022/058233
International Filing Date
01.09.2022
Title **
[English]
SUBSTITUTION OF NUCLEOTIDE BASES IN SELF-AMPLIFYING MESSENGER RIBONUCLEIC ACIDS
[French]
SUBSTITUTION DE BASES NUCLÉOTIDIQUES DANS DES ACIDES RIBONUCLÉIQUES MESSAGERS AUTO-AMPLIFICATEURS
Applicants **
GLAXOSMITHKLINE BIOLOGICALS SA
Rue de l'Institut 89
B-1330 Rixensart, BE
Inventors
KONG, Qiongman
14200 Shady Grove Road
Rockville, Maryland 20850, US
MARUGGI, Giulietta
14200 Shady Grove Road
Rockville, Maryland 20850, US
ROY, Varnika
14200 Shady Grove Road
Rockville, Maryland 20850, US
YU, Dong
14200 Shady Grove Road
Rockville, Maryland 20850, US
ZHANG, Meng
14200 Shady Grove Road
Rockville, Maryland 20850, US
Priority Data
63/240,502
03.09.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 6295 | |
| EPO | Filing, Examination | 18862 | |
| Japan | Filing | 587 | |
| South Korea | Filing | 574 | |
| USA | Filing, Examination | 10910 |
Total: 37228 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Provided herein are RNA that: are collectively self-amplifying in an intracellular environment, comprise N1-methylpseudouridines and uridines, and have a mole percentage or mole proportion of the N1-methylpseudouridines to the total of the uridines and the N1-methylpseudouridines or a mole ratio of the N1-methylpseudouridines to the uridines.[French]
L'invention concerne des ARN qui sont collectivement auto-amplificateurs dans un environnement intracellulaire, comprennent des N1-méthylpseudouridines et des uridines, et ont un pourcentage molaire ou une proportion molaire des N1-méthylpseudouridines par rapport au total des uridines et des N1-méthylpseudouridines ou un rapport molaire des N1-méthylpseudouridines par rapport aux uridines.